XtalPi (HKEX: 2228.HK) announced today that its biologics discovery division Ailux Biologics has entered into a strategic licensing agreement with Belgium-based global biopharmaceutical leader UCB (Euronext: UCB). Under the agreement, UCB gains access to XTALPI’s proprietary XtalFold™ AI platform for macromolecular drug discovery and engineering.
Platform Capabilities
The XtalFold™ suite enables rapid, high-accuracy structural modeling critical to biologic development stages including:
– Antigen design & epitope mapping
– Affinity maturation strategies
– pH-sensitive modification
– Bispecific antibody engineering
Validated through rigorous benchmarking, XtalFold™ demonstrates industry-leading performance in modeling complex interactions at antibody-antigen interfaces – a persistent challenge in monoclonal antibody development.
“UCB exemplifies how computational approaches can drive differentiated therapeutics. We’re honored to empower their R&D with AI-driven structural insights that accelerate life-changing discoveries.”
Dr. Jian Ma, CEO of XtalPi Inc.
“Following the Nobel Prize recognition for protein structure prediction, XtalFold™ represents industrialized deployment of this breakthrough. As a fully validated solution, it’s becoming the new standard across biologics development.”
Daniel Lightwood, Head of Antibody Discovery at UCB
“After exhaustive comparative testing, we’re confident XtalFold™ will enhance our ability to rapidly identify high-quality antibody candidates, ultimately delivering novel therapies to patients faster.”
Dr. Alexander Hillisch, Global Head of CADD at UCB
